🔗 Permalink

Inventor profile of:

Felix Bachmann

City:

Basel

Country:

Switzerland

Published Applications:

Last publication date:

2022-11-24

Top Assignees for applications by Felix Bachmann

The entities that hold a legal rights for patent applications filed by inventor Bachmann Felix:

BASILEA PHARMACEUTICA AG 14 Basel, Switzerland
Taleda Pharmaceutical Company Limited 1 Osaka-shi, Japan
RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG 1 Heidelberg, Germany
Basilea Pharmaceutica AG 1 , Switzerland
Basilea Pharmaceutica International AG 1 Basel, Switzerland
Takeda Pharmaceutical Company Limited 1 Osaka, Japan

Recent patent applications by Bachmann Felix

Felix Bachmann from Basel, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2022-11-24

US20220370418A1

Human necessities

PHARMACEUTICAL COMBINATIONS COMPRISING A FURAZANOBENZIMIDAZOLES AND A CD40 AGONIST FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES

#2 | 2022-02-03

US20220031670A1

Human necessities

PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES

#3 | 2020-12-17

US20200390749A1

Human necessities

Pharmaceutical combinations for use in the treatment of neoplastic diseases

#4 | 2019-01-10

US20190010536A1

Chemistry; metallurgy

Use of phospho-Akt as a biomarker of drug response

#5 | 2018-12-20

US20180364254A1

Physics

Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles

#6 | 2018-10-25

US20180306790A1

Physics

USE OF EB1 AS A BIOMARKER OF DRUG RESPONSE

#7 | 2017-05-04

US20170122934A1

Physics

Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles

#8 | 2016-11-03

US20160320397A1

Physics

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

#9 | 2014-03-20

US20140080872A1

Chemistry; metallurgy

Use of phospho-Akt as a biomarker of drug response

#10 | 2014-02-13

US20140045897A1

Physics

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

#11 | 2014-01-23

US20140024686A1

Physics

Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles

#12 | 2014-01-02

US20140005237A1

Physics

Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles

#13 | 2013-12-26

US20130345263A1

Physics

Use of stathmin as a biomarker of drug response to furazanobenzimidazoles

#14 | 2012-10-18

US20120264792A1

Chemistry; metallurgy

Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

#15 | 2008-11-20

US20080287681A1

Chemistry; metallurgy

Substituted benzimidazoles and their use for inducing apoptosis

#16 | 2008-09-11

US20080221171A1

Chemistry; metallurgy

Phenylaminopyridines

#17 | 2007-07-19

US20070167505A1

Chemistry; metallurgy

Substituted benzimidazoles and their use for inducing apoptosis

#18 | 2007-03-22

US20070066670A1

Chemistry; metallurgy

Substituted benzimidazoles and their use for inducing apoptosis

#19 | 2007-03-15

US20070060570A1

Chemistry; metallurgy

Sulfopyrroles

#20 | 2007-02-22

US20070043061A1

Chemistry; metallurgy

Furazanobenzimidazoles

#21 | 2006-09-14

US20060205739A1

Chemistry; metallurgy

Aroylfuranes and aroylthiophenes

#22 | 2005-06-16

US20050130237A1

Physics

High throughput screening method for compounds with non-, pro-, or anti-apoptotic or proliferative or necrotic activity

InventorID:

587859 ⎘